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Abstract
The prevalence of type 2 diabetes and insulin resistance has risen dramatically over the last decades.
Excess energy intake resulting in obesity and dysregulation of white adipose tissue (WAT) are important
factors contributing to the development of these metabolic diseases. The objective of this thesis was to
investigate the role of adipocyte-expressed Fas (CD95) in the development of obesity-induced insulin
resistance. In addition, insulin sensitivity of large and small adipocytes of obese white adipose tissue
was investigated and compared. Activation of the Fas signalling pathway in cultured 3T3-L1 adipocytes
leads to increased secretion of pro-inflammatory cytokines like IL-6 and KC (murine analogue of IL-8).
Moreover, Fas activation in 3T3-L1 adipocytes has negative effects on insulin sensitivity as shown by
reduced insulin-stimulated glucose uptake. In vivo, Fas expression is increased in isolated adipocytes of
insulin resistant mice and in adipose tissue of obese and diabetic patients. Adipocyte-specific
Fas-knockout (AFasKO) mice were partly protected from HFD-induced deterioration of glucose
homeostasis, and their levels of pro-inflammatory factors in WAT were reduced. Moreover, AFasKO
mice did not develop hepatic steatosis and maintained hepatic insulin sensitivity. Thus, Fas activation in
adipocytes contributes to adipose tissue inflammation, hepatic steatosis and insulin resistance induced
by obesity. Hypertrophic adipocytes, a consequence of obesity, are known to secrete higher amounts of
pro-inflammatory factors compared to small adipocytes. Thus, we hypothesized that large adipocytes
may be more insulin resistant. Interestingly, we found that insulin sensitivity did not differ between
small and large adipocytes isolated from the epididymal fat pad of obese mice. However, large
adipocytes secreted higher amounts of free fatty acids (FFA) compared to small adipocytes under basal
conditions. In conclusion, “dysregulated” adipocytes in obese white adipose tissue contribute to the
development of local and/or systemic insulin resistance. Large, lipid loaded adipocytes secrete higher
amount of FFA, which might negatively affect insulin sensitivity. Moreover, the Fas (CD95) pathway is
up-regulated in obesity and seems to contribute to local and systemic insulin resistance via changes in
the secretion pattern of cytokines.
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1 SUMMARY  
The prevalence of type 2 diabetes and insulin resistance has risen 
dramatically over the last decades. Excess energy intake resulting in 
obesity and dysregulation of white adipose tissue (WAT) are important 
factors contributing to the development of these metabolic diseases. The 
objective of this thesis was to investigate the role of adipocyte-expressed 
Fas (CD95) in the development of obesity-induced insulin resistance. In 
addition, insulin sensitivity of large and small adipocytes of obese white 
adipose tissue was investigated and compared. 
Activation of the Fas signalling pathway in cultured 3T3-L1 
adipocytes leads to increased secretion of pro-inflammatory cytokines like 
IL-6 and KC (murine analogue of IL-8). Moreover, Fas activation in 3T3-L1 
adipocytes has negative effects on insulin sensitivity as shown by reduced 
insulin-stimulated glucose uptake. In vivo, Fas expression is increased in 
isolated adipocytes of insulin resistant mice and in adipose tissue of obese 
and diabetic patients. Adipocyte-specific Fas-knockout (AFasKO) mice were 
partly protected from HFD-induced deterioration of glucose homeostasis, 
and their levels of pro-inflammatory factors in WAT were reduced. 
Moreover, AFasKO mice did not develop hepatic steatosis and maintained 
hepatic insulin sensitivity. Thus, Fas activation in adipocytes contributes to 
adipose tissue inflammation, hepatic steatosis and insulin resistance 
induced by obesity. 
Hypertrophic adipocytes, a consequence of obesity, are known to 
secrete higher amounts of pro-inflammatory factors compared to small 
adipocytes. Thus, we hypothesized that large adipocytes may be more 
insulin resistant. Interestingly, we found that insulin sensitivity did not differ 
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between small and large adipocytes isolated from the epididymal fat pad of 
obese mice. However, large adipocytes secreted higher amounts of free 
fatty acids (FFA) compared to small adipocytes under basal conditions.  
In conclusion, “dysregulated” adipocytes in obese white adipose 
tissue contribute to the development of local and/or systemic insulin 
resistance. Large, lipid loaded adipocytes secrete higher amount of FFA, 
which might negatively affect insulin sensitivity. Moreover, the Fas (CD95) 
pathway is up-regulated in obesity and seems to contribute to local and 
systemic insulin resistance via changes in the secretion pattern of 
cytokines. 
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1 ZUSAMMENFASSUNG 
 Die Prävalenzen von Typ 2 Diabetes und Insulin Resistenz haben in 
den letzten Jahren massiv zugenommen. Übergewicht, verursacht durch 
einen Überschuss an Energiezufuhr, sowie eine Disregulierung des 
weissen Fettgewebes sind wichtige Faktoren, die zu diesen metabolischen 
Krankheiten beitragen. Das Ziel dieser Arbeit war es, den Einfluss einer 
Fas-Rezeptor (CD95)-Aktivierung in Fettzellen bei der Entstehung der 
übergewichts-bedingten Insulinresistenz zu untersuchen. Zusätzlich wurde 
die Insulinsensitivität von kleinen und grossen Fettzellen, welche aus dem 
gleichen Fettgewebe übergewichtiger Mäuse isoliert wurden, analysiert und 
verglichen. 
Die Aktivierung des Fas-Signalweges in kultivierten Fettzellen (in 
vitro) führt zu einer vermehrten Sekretion von Entzündungsfaktoren wie IL-6 
und KC (murines IL-8) aus diesen Zellen. Zudem vermindert die Aktivierung 
des Fas-Rezeptors die Insulinsensitivität von 3T3-L1 Adipozyten. In vivo ist 
die Expression des Fas-Rezeptors in Fettzellen insulinresistenter Mäuse 
sowie im Fettgewebe übergewichtiger und diabetischer Patienten erhöht. 
Mäuse, bei denen der Fas-Rezeptor spezifisch in Fettzellen ausgeschaltet 
wurde (AFasKO), sind teilweise vor einer Verschlechterung des 
Zuckerstoffwechsels (Glukosetoleranz), welche durch eine fettreiche 
Ernährung induziert wurde, geschützt. Zudem exprimiert das Fettgewebe 
dieser Mäuse weniger Entzündungsfaktoren. AFasKO Mäuse entwickeln, 
im Gegensatz zu Wildtyp-Mäusen, keine Fettleber bei fettreicher 
Ernährung. Auch die Insulinsensitivität der Leber bleibt erhalten. Folglich 
trägt die Aktivierung des Fas-Rezeptors in Fettzellen zur Übergewichts-
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induzierten Entzündung des Fettgewebes, zur Entstehung der Fettleber 
sowie der Insulinresistenz bei. 
Hypertrophe Fettzellen, welche sich vermehrt im Fettgewebe von 
Übergewichtigen finden, sezernieren mehr Entzündungsfaktoren als kleine 
Fettzellen. Wir stellten die Hypothese auf, dass hypertrophe Fettzellen 
vermehrt insulinresistent sind. Überraschenderweise fanden wir, dass die 
Insulinsensitivität zwischen kleinen und grossen Fettzellen, welche aus dem 
gleichem Fettgewebe übergewichtiger Mäuse isoliert wurden, gleich ist. 
Grosse Fettzellen sezernieren aber mehr freie Fettsäuren und tragen 
möglicherweise so zu einer vermehrten Ganzkörper-Insulinresistenz bei. 
Zusammfassend lässt sich sagen, dass eine Disregulation des 
Fettzellstoffwechsels, wie sie im Rahmen einer Adipositas auftreten kann, 
eine wichtige Rolle in der Entstehung der lokalen und systemischen 
Insulinresistenz spielt. Grosse, lipidreiche Fettzellen sezernieren vermehrt 
freie Fettsäuren. Fettsäuren können die Insulinsensitivität sowohl lokal, im 
Fettgewebe, wie auch systemisch vermindern. Des Weiteren können 
Fettzellen ihr Sekretionsmuster aufgrund vermehrter Fas-Rezeptor-
Aktivierung verändern. Eine vermehrte Freisetzung von 
Entzündungsfaktoren kann sowohl lokal wie auch systemisch (hepatisch) 
eine Insulinresistenz induzieren. 
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2 INTRODUCTION 
2.1 Type 2 diabetes and insulin resistance 
2.1.1 Type 2 diabetes 
The prevalence of type 2 diabetes has risen dramatically over the 
last two decades. Moreover, it is anticipated that the worldwide incidence of 
this metabolic disease will increase by about 70% over the next 20 years. 
Type 2 diabetes can lead to blindness, end-stage renal disease, and non-
traumatic loss of limbs. Besides generating enormous medical costs, type 2 
diabetes is the 5th leading cause of death [1]. In addition to a genetic 
predisposition, acquired factors such as obesity and sedentary lifestyle play 
an important role in its pathogenesis. While type 1 diabetes mellitus is 
defined by a heterogeneous disorder characterized by β-cell loss [2], the 
onset of type 2 diabetes is most often preceded by insulin resistance, 
characterised by a reduced cellular sensitivity to insulin. During early stages 
of insulin resistance, pancreatic β-cells can compensate for attenuated 
cellular insulin response by increasing insulin production and secretion and, 
thus, raising insulin levels (hyperinsulinemia). However, type 2 diabetes 
finally develops as β-cells fail to compensate for peripheral insulin 
resistance [3].  
 
2.1.2 Insulin 
The discovery of the protein hormone insulin 1921 was one of the 
major medical advances of the last century. Insulin is synthesized and 
secreted by pancreatic β-cells in the islet of Langerhans. Insulin binding to 
the insulin receptor, a protein tyrosine kinase composed of two α- and two 
β-subunits, leads to its activation via autophosphorylation of the β-subunit. 
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Further downstream, cell and tissue specific signalling pathways can be 
activated and/or inhibited [4]. Insulin is a pleiotropic hormone with several 
effects on metabolism and body homeostasis. The major function of insulin 
is to lower circulating blood glucose levels, which is mainly mediated by 
insulin-stimulated glucose uptake into skeletal muscle (and to a minor part 
adipose tissue and even kidney) and by insulin-induced suppression of 
glucose release (gluconeogenesis and glycogenolysis) from the liver. 
Inhibition of free fatty acid (FFA) release from adipose tissue and 
stimulation of protein synthesis in skeletal muscle are other important 
metabolic functions of insulin [5].  
 
2.1.3 Insulin signalling  
Insulin-stimulated glucose uptake into adipose tissue and skeletal 
muscle is mediated by the facilitative glucose transporter GLUT4. Upon 
interaction of insulin with its receptor at the plasma membrane, the insulin 
receptor tyrosine kinase is activated, leading to phosphorylation of the 
insulin receptor substrate (IRS) family of proteins on several tyrosine 
residues. Tyrosine-phosphorylated IRS serve as docking sites for 
phospatidylinositol 3-kinase (PI3-K) (Fig. 1). Downstream of PI3-K, the 
serine/threonine protein kinase Akt (also called  protein kinase B, PKB) as 
well as the atypical protein kinase C isoforms λ and ζ are activated and 
contribute to insulin regulated GLUT4 translocation to the plasma 
membrane [6]. Besides glucose uptake, insulin promotes glycolysis as well 
as glycogen and protein synthesis in skeletal muscle. In adipocytes, insulin 
decreases FFA release (lipolysis), via decreased activity of protein kinase A 
(PKA) and, further downstream, hormone sensitive lipase (HSL). Moreover, 
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insulin stimulates FFA uptake via activation of lipoprotein lipases (LPL) into 
adipocytes and increases the rate of intracellular lipid synthesis [7].  
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Fig. 1 Insulin signalling 
Propagation of the insulin signal involves activation of PI3-K and of its downstream 
target Akt leading to increased glucose transport, elevated glycogen and protein 
synthesis and/or suppressed gluconeogenesis (liver). Moreover, lipolysis is inhibited 
in adipocytes via decreased activation of PKA. In addition, mitogenic pathways 
leading to cell proliferation can be induced via activation of mitogen activated protein 
kinases (MAPK). P: phosphorylation [6-9]. 
 
The liver plays an important role in the maintenance of blood glucose 
homeostasis. Although there are no insulin sensitive glucose transporters in 
the liver, insulin plays an important role in the regulation of hepatic glucose 
turnover. Insulin inhibits glucose output from the liver by down regulating 
the rate limiting enzymes of gluconeogenesis (phosphoenolypyruvate 
carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase)) and by 
decreasing the rate of glycogenolysis. At the same time, insulin increases 
hepatic lipid and glycogen synthesis, the latter via activation of glycogen 
synthase [8]. 
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2.1.4 Insulin resistance 
In insulin resistance, transmission of the insulin signal is reduced in 
one or several locations. In particular, phosphorylation of IRS on specific 
serine residues inhibits tyrosine phosphorylation of IRS by decreasing its 
affinity to the insulin receptor kinase, resulting in reduced transmission of 
the insulin signal. Several cytokines such as tumour necrosis factor-alpha 
(TNF-α) as well as FFAs were shown to activate serine/threonine kinases 
leading to phosphorylation of IRS on specific serine residues [10-12]. 
Numerous studies implicated activation of c-Jun N-terminal kinase (JNK) 
and/or increased production of nuclear factor-kappa B (NF-κB) with 
increased serine phosphorylation of IRS, and hence, with the induction of 
insulin resistance [13, 14]. Moreover, cytokine-induced expression of SOCS 
proteins (suppressors of cytokine signalling) was shown to inhibit insulin 
signalling by preventing binding of IRS to the tyrosine-phosphorylated 
insulin receptor [15]. Besides impaired insulin signalling at the level of IRS, 
there are other „critical nodes“ that can be affected in insulin resistance [9]. 
PI3-K generates phosphatidylinositol (3,4,5)-triphosphate (PIP3), a lipid 
second messenger that is important for the activation of Akt/PKB further 
downstream (Fig. 1). Phosphatases such as phosphatase and tensin 
homologue (PTEN) can dephosphorylate and inactivate PIP3 and therefore 
negatively affect insulin signalling. Moreover, the phosphorylation of 
Akt/PKB can be directly inhibited by several mechanisms [9]. 
Muscle, adipose and hepatic insulin resistance contribute all to the 
development of type 2 diabetes. Decreased insulin-stimulated glucose 
uptake by skeletal muscle and decreased suppression of hepatic glucose 
production (gluconeogenesis) are responsible for the excessive rise in 
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plasma glucose levels upon glucose ingestion, i.e. postprandial 
hyperglycemia (in the absence of a compensatory rise in insulin secretion). 
Moreover, insulin resistant adipocytes fail to respond to the anti-lipolytic 
actions of insulin, which leads to elevated plasma FFA. Chronically 
increased FFA levels may have deleterious effects on hepatic and skeletal 
muscle insulin sensitivity as well as on beta-cell function and therefore 
further worsen glucose homeostasis [16]. 
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2.2 White adipose tissue and obesity 
2.2.1 White adipose tissue (WAT) 
Adipogenesis, the development of adipose tissue, includes the 
differentiation of preadipocytes of mesenchymal origin into mature 
adipocytes. During differentiation, specific transcription factors like 
proliferator-activator receptor γ (PPARγ) and members of the CCAATT 
enhancer-binding proteins (C/EBPs) are activated and lead to the 
expression of adipocyte-specific proteins like GLUT4 and fatty acid binding 
protein 4 (FABP4). Besides adipocytes, WAT consists of other cell types 
such as macrophages, fibroblasts, blood cells, endothelial cells and 
preadipocytes forming the stromal vascular fraction (SVF). This 
heterogeneity of the adipose tissue leads to an extensive paracrine 
crosstalk between the different cells. Moreover, factors secreted from the 
WAT, like cytokines or chemokines, can affect several cells and tissues of 
the entire body in an endocrine manner (Fig. 2) [17].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Adipose derived factors 
White adipose tissue (WAT) consists of several cells like adipocytes, macrophages 
and endothelial cells. Those cells secret different factors (adipokines, chemokines, 
metabolites e.g.) that act in a paracrine manner within the WAT, and in an endocrine 
manner affecting systemic homeostasis. Image adopted from [17]. 
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Anatomically, adipose tissue depots can be divided in subcutaneous 
locations (approx. 80% of total body fat) and internal locations (approx. 20% 
of total body fat). In obesity, two main types of fat distribution can be 
distinguished: an “android obesity” type (“apple shaped”) with increased 
abdomino-visceral fat accumulation, and a “gynoid obesity” type (“pear 
shaped”) with increased subcutaneous fat [17].  
  
2.2.2 Obesity 
Obesity has reached epidemic proportions in Europe. The 
prevalence of obesity has increased approximately 30% over the past 10 to 
15 years, rendering it an important factor for several diseases like type 2 
diabetes and arteriosclerosis [18]. In particular, the number of overweight 
and obese children and adolescents has been increasing. In Switzerland, 
approximately every 5th child is overweight [19]. Obesity is caused by 
caloric intake exceeding energy expenditure, and is associated with an 
increased number and/or size of white adipocytes storing the excessive 
energy in the form of triglycerides [20]. Under a prolonged period of positive 
energy balance, adipose tissue mass increases by enlargement of existing 
adipocytes (hypertrophy). Additionally, WAT expansion can progress by an 
increase in cell number (hyperplasia) [17]. Adipocyte hypertrophy was 
proposed to be causative in inducing adipose tissue dysfunction in obesity, 
since large adipocytes may secrete higher levels of pro-inflammatory 
cytokines [21]. On a more metabolic level, hypertrophic adipocytes may 
exhibit a reduced capacity to store and retain FFAs, leading to elevated 
levels of circulating FFAs [22].  
 14
In the U.S. more than 80% of patients with type 2 diabetes are 
overweight, pointing towards an important role of obesity in the 
development of type 2 diabetes [16]. Besides total body fat mass, the 
distribution of body fat seems to play an important role. Subjects with 
preferential upper body fat accumulation (“apple shaped”) are at higher risk 
for insulin resistance and type 2 diabetes than people with increased 
percentage of lower body fat accumulation (“peer shaped”). Probably, 
increased amounts of visceral adipose tissue in the “apple shaped” obesity 
contributes to this phenomenon, which leads to increased release of FFA 
and pro-inflammatory cytokines into the portal vein and the liver, 
respectively [16].  
Importantly, WAT is needed for proper glucose homeostasis, as 
individuals with diminished fat mass (lipodystrophy) can develop insulin 
resistance. Insufficient adipose tissue mass in patients with lipodystrophy 
leads to an ectopic storage of FFA and triglycerides in other tissues (liver, 
skeletal muscle), and ectopic fat storage in skeletal muscle and liver 
correlates positively with insulin resistance in these tissues. These 
observations suggest that it is not merely the increase in adipose tissue 
mass per se that alters the function of target organs in obesity [16, 23], but 
also the location and “quality” of the white adipose tissue. Likewise, 
increasing intra-abdominal fat mass by transplantation of fat pads from non-
obese mice had no negative effect on glucose homeostasis, but even 
increased insulin sensitivity [24]. This effect might be due to the fact that the 
transplanted intra-abdominal fat was stitched to the peritoneum and 
therefore was drained systemically via the vena cava and not by the portal 
vein. 
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2.2.3 White adipose tissue and insulin resistance 
Adipose tissue plays an important role in the 
development/pathogenesis of insulin resistance. For many years, the sole 
function of white adipose tissue (WAT) was considered to be the storage of 
triglycerides. However, findings over the last two decades identified WAT as 
an important endocrine organ secreting different hormone-like factors 
(adipokines), FFAs as well as cytokines and thereby affecting metabolism 
locally and systemically [17, 25]. In obesity and insulin resistance, 
production of certain adipokines is reduced (e.g. adiponectin), whereas 
secretion of other adipokines/cytokines like IL-6 or TNF-α is increased [16]. 
This “dysfunctional” secretion pattern is characteristic for obese and/or 
diabetic subjects and may be related to increased fat accumulation. In this 
regard, hypertrophic adipocytes, a consequence of excess energy intake, 
are known to secrete increased levels of pro-inflammatory cytokines 
compared to small adipocytes [21].  
Moreover, adipose tissue of obese subjects is infiltrated by 
macrophages and other inflammatory cells suggesting a role for 
inflammation in the pathogenesis of obesity and diabetes. The infiltrating 
inflammatory cells secrete different cytokines such as IL-1β, IL-6, IL-8 (KC), 
TNF-α and MCP-1, which in turn alter the expression and secretion pattern 
of adipokines and cytokines in adipose tissue. As a consequence, insulin 
sensitivity is impaired locally and systemically [11, 26, 27]. In mice, 3 days 
of high fat diet (HFD) is enough to induce a significant infiltration of intra-
abdominal WAT by neutrophils, whereas longer periods of HFD leads to an 
accumulation of macrophages in WAT [28-33]. There are different types of 
macrophages in adipose tissue. Resident macrophages, which are 
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predominantly found in WAT of lean subjects, are thought to be alternatively 
activated and mainly producing anti-inflammatory cytokines like IL-10. Bone 
marrow-derived macrophages that infiltrate adipose tissue in obesity, 
however, are classically activated and secrete pro-inflammatory factors like 
TNFα and IL-6. Moreover, diet-induced obesity leads to a shift in 
polarization of resident, alternatively activated macrophages towards 
classically activated, pro-inflammatory macrophages [34]. 
Besides inflammatory processes induced by macrophages and other 
immune cells, insulin resistance in adipose tissue can also be evoked by 
endoplasmic reticulum stress (ER stress). FFAs were shown to induce ER 
stress in several cells by provoking the unfolded protein response (UPR). 
The UPR, a source of stress signalling, can activate JNK or promote 
oxidative stress, which are both known to induce insulin resistance [35]. 
 
2.2.4 Systemic cross-talk 
Factors that are secreted by adipose tissue (Fig. 2) can affect other 
tissues and organs of the body. Importantly, skeletal muscle and the liver, 
two key components in the control of glucose homeostasis, may be 
affected, i.e. hepatic and muscular insulin sensitivity can be impaired by 
obesity-induced alterations in adipokine secretion and by elevated cytokine 
and FFA release (Fig. 3) [26, 36, 37]. 
Particularly, increased delivery of FFA from expanded adipose tissue 
to the liver can contribute to an excessive accumulation of hepatic 
triglycerides, which is characteristic for nonalcoholic fatty liver disease 
(NAFLD). In addition, cytokines seem to contribute to the pathogenesis of 
NAFLD [38]. Especially, IL-6 and TNF-α were suggested to play a 
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significant role in the development of fatty liver since they are up-regulated 
in patients with NAFLD [39-41].  
 
 
 
 
 
 
 
 
 
 
Fig. 3 Systemic cross-talk 
In obesity, fat tissue secretes several factors that can affect glucose metabolism 
systemically. For example, TNF-α, IL-6 or FFA secreted by WAT can decrease 
insulin sensitivity in liver and skeletal muscle, therefore negatively affecting glucose 
homeostasis. 
 
   
TNF-a
IL-6
FFA
Insulin 
sensitivity
 18
2.3 Fas (CD95) 
2.3.1 Apoptosis 
Fas (also known as CD95) is a member of the tumour-necrosis factor 
receptor superfamily and plays a central role in the regulation of 
programmed cell death (apoptosis) in many cell types. Fas is expressed in 
most tissues, and resistance to Fas receptor-mediated cell death is 
associated with the progression and metastasis of tumours. Activation of 
the Fas signalling pathway by binding of Fas ligand (FasL) to Fas initiates a 
caspase cascade that culminates in apoptosis. Trimerisation of the Fas 
receptor is necessary for the recruitment of Fas associated death domain 
(FADD) and formation of the death inducing signalling complex (DISC). 
Further downstream, caspases 8 (FLICE) and caspase 3 (the “effector 
caspase”) are activated and provoke apoptosis [42]. The Fas-mediated 
death signal can be inhibited by the FLICE-inhibitory protein (FLIP), which 
competes with caspase 8 for binding to FADD.  
 
2.3.2 Non-apoptotic pathway 
In addition to this well-established role in apoptosis, activation of Fas 
can also induce non-apoptotic signalling pathways including cell 
proliferation and inflammation [1, 43]. Importantly, Fas activation was shown 
to induce the secretion of cytokines such as IL-1α, IL-1β, IL-6, IL-8 (KC) and 
MCP-1 in different cell lines and tissues (Fig. 4) [44-48]. The signalling 
pathways involved in these Fas-mediated biological effects are only recently 
being unravelled. Activation of the extracellular signal-related kinase (ERK) 
[49], NF-κB [43, 50], or JNK [51-53] are possible mediators of the non-
apoptotic Fas signalling pathway. 
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Fig. 4 Fas (CD95) signalling 
Activation of the Fas signalling pathway by binding of Fas ligand (FasL) can lead to 
apoptosis via activation of caspases. However, non-apoptotic pathways leading to 
induction of cytokines like IL-6, IL-8 or MCP-1 can also be activated in several 
tissues and cell lines. 
 
Factors modulating the balance between Fas-induced apoptotic and 
non-apoptotic pathways are not well known, but there is increasing 
evidence that FLIP may orchestrate this balance. FLIP appears to switch 
Fas activation from acting as a pro- to an non-apoptotic signalling event, 
leading to proliferation and/or inflammation [54, 55]. This effect of FLIP 
appears to depend on the strength of the Fas stimulus. At low FasL 
concentration, FLIP seems to be able to block apoptotic pathways, whereas 
at high doses this blocking effect is abolished, and apoptosis occurs [56]. In 
addition, death domain-associated protein (Daxx), which can be recruited to 
the Fas receptor signalling complex, may modulate the balance between 
Fas-induced apoptotic and non-apoptotic pathways by interacting with 
apoptosis signalling kinase 1 (ASK1) [42, 57]. Moreover, internalization of 
Apoptosis IL-6, IL-8, MCP-1 e.g.
Fas
FasL
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the Fas receptor upon FasL binding seems to play a role for downstream 
signalling. Possibly, receptor mediated endocytosis is required for efficient 
activation of the caspase cascade leading to cell death, whereas it is not 
required for non-apoptotic pathways induced by Fas [58].  
 
2.3.3 Fas and insulin resistance 
As mentioned, Fas activation in several tissues and cells induces the 
secretion of different cytokines such as IL-1β, IL-6 and MCP-1. Intriguingly, 
several of theses pro-inflammatory cytokines are increasingly produced and 
secreted in obesity and insulin resistance. Thus, Fas activation may be a 
modulator of cytokine production in obesity and, thus, influencing obesity-
induced insulin resistance. In addition, (non-apoptotic) Fas signaling can 
activate ERK, JNK and NF-κB, factors that are known to impair insulin 
sensitivity in several cells and tissues [13, 14]. 
Interestingly, recent studies in humans revealed an association of 
promoter alterations in the Fas and FasL gene with type 2 diabetes and 
insulin resistance [59], thus suggesting a potential role of these genes in the 
development of insulin resistance and/or type 2 diabetes.  
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2.4 Hypotheses 
 Fas (CD95) activation in adipocytes contributes to obesity-induced 
insulin resistance 
 Large adipocytes isolated from obese mice are more insulin resistant 
than small adipocytes harvested from the same fat pad 
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3 METHODS 
3.1 Diverse methods 
Methods used during the thesis are described in the Results section 
(Appendix; included manuscripts). Recently, the hyperinsulinaemic-
euglycaemic clamp technique was established in our laboratory. This 
technique is described in detail below. 
 
3.2 Hyperinsulinaemic-euglycaemic clamp 
The hyperinsulinaemic-euglycaemic clamp technique is presently the 
“gold standard” for measuring insulin sensitivity in vivo. In this method, 
insulin is infused via a catheter intravenously to raise the insulin 
concentration to supraphysiological levels. At the same time, glucose is 
infused to maintain blood glucose at euglycaemic levels (5-6 mmol/l; 
“clamping” of blood glucose levels) [60].  
Seven days before clamping, mice are anesthetized with isofluran 
and a catheter (MRE 025, Braintree Scientific, Braintree, MA, USA) is 
inserted into the left jugular vein and exteriorized at the back of the neck. 
Upon recovery, only mice that have regained > 90% of their preoperative 
weight are studied. After a fasting period of 5 hours, 3-[3H]glucose (3H-G) 
(0.1μCi/min; PerkinElmer, Schwerzenbach, Switzerland) is infused for 80 
min and blood is collected from the tail tip for basal turnover calculation. 
After basal sampling, insulin (18 mU/kg x min) is infused for 90 min. 
Euglycaemia is maintained by periodically adjusting a variable infusion of 
20% glucose with a syringe pump (TSE Systems, Bad Homburg, Germany). 
The glucose infusion rate is calculated as the mean of the steady state 
infusion which is reached after about 60 min of insulin and glucose infusion 
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(Fig. 4). A blood sample is collected after steady state infusion. The glucose 
turnover rate is calculated by dividing the rate of 3H-G infusion by the 
plasma 3H-G specific activity. Hepatic glucose production is calculated by 
subtracting the glucose infusion rate from the glucose turnover rate [61]. 
 
Fig. 4 Hyperinsulinaemic-euglycaemic clamp 
After a prime infusion of 3-[3H]glucose for 80 min, insulin and 3-[3H]glucose are 
infused via catheter into the jugular vein (time point 0 min). Left graph: Blood glucose 
levels during a hyperinsulinaemic-euglycaemic clamp of WT and AFasKO mice (see 
attached manuscript). Blood glucose levels are “clamped” at 5-6 mmol/l (see dotted 
line). Right graph: To maintain euglycaemia, increasing amounts of glucose needs to 
be infused. Glucose infusion rates increase until a “steady state” infusion is reached 
after about 60 min. Steady state glucose infusion is calculated as the mean infusion 
rate between 60 and 90 min.  
 
0 10 20 30 40 50 60 70 80 90
0.00
0.25
0.50
0.75
1.00
W T
AFasKO
Time (min)
G
lu
co
se
 in
fu
si
on
 ra
te
(m
l/h
)
0 10 20 30 40 50 60 70 80
0
2
4
6
8
10
12
W T
AFasKO
Time (min)
B
lo
od
 g
lu
co
se
 l
ev
el
s
(m
m
ol
/l)
 24
4 REFERENCES 
 
1. Petersen, K.F. and G.I. Shulman, Etiology of insulin resistance. Am J Med, 
2006. 119(5 Suppl 1): p. S10-6. 
2. Miura, J. and Y. Uchigata, [Latest overview of type 1 diabetes mellitus]. 
Nippon Rinsho, 2008. 66(7): p. 1397-404. 
3. Evans, J.L., et al., Oxidative stress and stress-activated signaling pathways: 
a unifying hypothesis of type 2 diabetes. Endocr Rev, 2002. 23(5): p. 599-
622. 
4. Cohen, P., The twentieth century struggle to decipher insulin signalling. Nat 
Rev Mol Cell Biol, 2006. 7(11): p. 867-73. 
5. Jellinger, P.S., Metabolic consequences of hyperglycemia and insulin 
resistance. Clin Cornerstone, 2007. 8 Suppl 7: p. S30-42. 
6. Thong, F.S., C.B. Dugani, and A. Klip, Turning signals on and off: GLUT4 
traffic in the insulin-signaling highway. Physiology (Bethesda), 2005. 20: p. 
271-84. 
7. Large, V., et al., Metabolism of lipids in human white adipocyte. Diabetes 
Metab, 2004. 30(4): p. 294-309. 
8. Postic, C., R. Dentin, and J. Girard, Role of the liver in the control of 
carbohydrate and lipid homeostasis. Diabetes Metab, 2004. 30(5): p. 398-
408. 
9. Taniguchi, C.M., B. Emanuelli, and C.R. Kahn, Critical nodes in signalling 
pathways: insights into insulin action. Nat Rev Mol Cell Biol, 2006. 7(2): p. 
85-96. 
10. Wellen, K.E. and G.S. Hotamisligil, Inflammation, stress, and diabetes. J 
Clin Invest, 2005. 115(5): p. 1111-9. 
11. Poirier, H., et al., Nutritional supplementation with trans-10, cis-12-
conjugated linoleic acid induces inflammation of white adipose tissue. 
Diabetes, 2006. 55(6): p. 1634-41. 
12. Hirosumi, J., et al., A central role for JNK in obesity and insulin resistance. 
Nature, 2002. 420(6913): p. 333-6. 
13. Hotamisligil, G.S., Inflammatory pathways and insulin action. Int J Obes 
Relat Metab Disord, 2003. 27 Suppl 3: p. S53-5. 
14. Gao, Z., et al., Serine phosphorylation of insulin receptor substrate 1 by 
inhibitor kappa B kinase complex. J Biol Chem, 2002. 277(50): p. 48115-
21. 
15. Ronn, S.G., N. Billestrup, and T. Mandrup-Poulsen, Diabetes and 
suppressors of cytokine signaling proteins. Diabetes, 2007. 56(2): p. 541-8. 
16. Bays, H., L. Mandarino, and R.A. DeFronzo, Role of the adipocyte, free 
fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: 
peroxisomal proliferator-activated receptor agonists provide a rational 
therapeutic approach. J Clin Endocrinol Metab, 2004. 89(2): p. 463-78. 
17. Frühbeck, G., Overview of Adipose Tissue and its Role in Obesity and 
Metabolic Disorders. Methods in Molecular Biology. Vol. 456. 2007, 
Totowa NJ: Humana Press. Chapter 1. 
18. Berghofer, A., et al., Obesity prevalence from a European perspective: a 
systematic review. BMC Public Health, 2008. 8: p. 200. 
19. Bovet, P., A. Chiolero, and F. Paccaud, [Epidemiology and prevention of 
obesity in children and adolescents]. Rev Med Suisse, 2008. 4(148): p. 650-
2, 654-6. 
 25
20. Fruhbeck, G., et al., The adipocyte: a model for integration of endocrine 
and metabolic signaling in energy metabolism regulation. Am J Physiol 
Endocrinol Metab, 2001. 280(6): p. E827-47. 
21. Skurk, T., et al., Relationship between adipocyte size and adipokine 
expression and secretion. J Clin Endocrinol Metab, 2007. 92(3): p. 1023-33. 
22. Lelliott, C. and A.J. Vidal-Puig, Lipotoxicity, an imbalance between 
lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord, 
2004. 28 Suppl 4: p. S22-8. 
23. Tiraby, C. and D. Langin, Conversion from white to brown adipocytes: a 
strategy for the control of fat mass? Trends Endocrinol Metab, 2003. 
14(10): p. 439-41. 
24. Konrad, D., A. Rudich, and E.S. Schoenle, Improved Glucose Tolerance in 
Mice Receiving Intraperitoneal Fat Tissue Transplant. Diabetologia, 2006. 
25. Scherer, P.E., Adipose tissue: from lipid storage compartment to endocrine 
organ. Diabetes, 2006. 55(6): p. 1537-45. 
26. Park, S.Y., et al., Unraveling the temporal pattern of diet-induced insulin 
resistance in individual organs and cardiac dysfunction in C57BL/6 mice. 
Diabetes, 2005. 54(12): p. 3530-40. 
27. Zick, Y., Ser/Thr phosphorylation of IRS proteins: a molecular basis for 
insulin resistance. Sci STKE, 2005. 2005(268): p. pe4. 
28. Weisberg, S.P., et al., Obesity is associated with macrophage accumulation 
in adipose tissue. J Clin Invest, 2003. 112(12): p. 1796-808. 
29. Yuan, M., et al., Reversal of obesity- and diet-induced insulin resistance 
with salicylates or targeted disruption of Ikkbeta. Science, 2001. 293(5535): 
p. 1673-7. 
30. Xu, H., et al., Chronic inflammation in fat plays a crucial role in the 
development of obesity-related insulin resistance. J Clin Invest, 2003. 
112(12): p. 1821-30. 
31. Arkan, M.C., et al., IKK-beta links inflammation to obesity-induced insulin 
resistance. Nat Med, 2005. 11(2): p. 191-8. 
32. Cai, D., et al., Local and systemic insulin resistance resulting from hepatic 
activation of IKK-beta and NF-kappaB. Nat Med, 2005. 11(2): p. 183-90. 
33. Elgazar-Carmon, V., et al., Neutrophils transiently infiltrate intra-
abdominal fat early in the course of high-fat feeding. J Lipid Res, 2008. 
49(9): p. 1894-903. 
34. Lumeng, C.N., J.L. Bodzin, and A.R. Saltiel, Obesity induces a phenotypic 
switch in adipose tissue macrophage polarization. J Clin Invest, 2007. 
117(1): p. 175-84. 
35. Gregor, M.G. and G.S. Hotamisligil, Adipocyte stress: The endoplasmic 
reticulum and metabolic disease. J Lipid Res, 2007. 
36. Klover, P.J., et al., Chronic exposure to interleukin-6 causes hepatic insulin 
resistance in mice. Diabetes, 2003. 52(11): p. 2784-9. 
37. Parekh, S. and F.A. Anania, Abnormal lipid and glucose metabolism in 
obesity: implications for nonalcoholic fatty liver disease. Gastroenterology, 
2007. 132(6): p. 2191-207. 
38. Greco, D., et al., Gene expression in human NAFLD. Am J Physiol 
Gastrointest Liver Physiol, 2008. 294(5): p. G1281-7. 
39. Carter-Kent, C., N.N. Zein, and A.E. Feldstein, Cytokines in the 
pathogenesis of fatty liver and disease progression to steatohepatitis: 
implications for treatment. Am J Gastroenterol, 2008. 103(4): p. 1036-42. 
 26
40. Crespo, J., et al., Gene expression of tumor necrosis factor alpha and TNF-
receptors, p55 and p75, in nonalcoholic steatohepatitis patients. 
Hepatology, 2001. 34(6): p. 1158-63. 
41. Wieckowska, A., et al., Increased hepatic and circulating interleukin-6 
levels in human nonalcoholic steatohepatitis. Am J Gastroenterol, 2008. 
103(6): p. 1372-9. 
42. Curtin, J.F. and T.G. Cotter, Live and let die: regulatory mechanisms in 
Fas-mediated apoptosis. Cell Signal, 2003. 15(11): p. 983-92. 
43. Wajant, H., K. Pfizenmaier, and P. Scheurich, Non-apoptotic Fas signaling. 
Cytokine Growth Factor Rev, 2003. 14(1): p. 53-66. 
44. Faouzi, S., et al., Anti-Fas induces hepatic chemokines and promotes 
inflammation by an NF-kappa B-independent, caspase-3-dependent 
pathway. J Biol Chem, 2001. 276(52): p. 49077-82. 
45. Farley, S.M., et al., Fas ligand-induced proinflammatory transcriptional 
responses in reconstructed human epidermis. Recruitment of the epidermal 
growth factor receptor and activation of MAP kinases. J Biol Chem, 2008. 
283(2): p. 919-28. 
46. Imamura, R., et al., Fas ligand induces cell-autonomous NF-kappaB 
activation and interleukin-8 production by a mechanism distinct from that 
of tumor necrosis factor-alpha. J Biol Chem, 2004. 279(45): p. 46415-23. 
47. Miwa, K., et al., Caspase 1-independent IL-1beta release and inflammation 
induced by the apoptosis inducer Fas ligand. Nat Med, 1998. 4(11): p. 
1287-92. 
48. Schaub, F.J., et al., Fas and Fas-associated death domain protein regulate 
monocyte chemoattractant protein-1 expression by human smooth muscle 
cells through caspase- and calpain-dependent release of interleukin-1alpha. 
Circ Res, 2003. 93(6): p. 515-22. 
49. Desbarats, J., et al., Fas engagement induces neurite growth through ERK 
activation and p35 upregulation. Nat Cell Biol, 2003. 5(2): p. 118-25. 
50. Legembre, P., et al., Induction of apoptosis and activation of NF-kappaB by 
CD95 require different signalling thresholds. EMBO Rep, 2004. 5(11): p. 
1084-9. 
51. Cahill, M.A., et al., CD95 (APO-1/Fas) induces activation of SAP kinases 
downstream of ICE-like proteases. Oncogene, 1996. 13(10): p. 2087-96. 
52. Rudel, T., et al., p21-activated kinase (PAK) is required for Fas-induced 
JNK activation in Jurkat cells. J Immunol, 1998. 160(1): p. 7-11. 
53. Yang, X., et al., Daxx, a novel Fas-binding protein that activates JNK and 
apoptosis. Cell, 1997. 89(7): p. 1067-76. 
54. Budd, R.C., W.C. Yeh, and J. Tschopp, cFLIP regulation of lymphocyte 
activation and development. Nat Rev Immunol, 2006. 6(3): p. 196-204. 
55. Maedler, K., et al., FLIP switches Fas-mediated glucose signaling in human 
pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci 
U S A, 2002. 99(12): p. 8236-41. 
56. Lavrik, I.N., et al., Analysis of CD95 threshold signaling: triggering of 
CD95 (FAS/APO-1) at low concentrations primarily results in survival 
signaling. J Biol Chem, 2007. 282(18): p. 13664-71. 
57. Salomoni, P. and A.F. Khelifi, Daxx: death or survival protein? Trends Cell 
Biol, 2006. 16(2): p. 97-104. 
58. Lee, K.H., et al., The role of receptor internalization in CD95 signaling. 
Embo J, 2006. 25(5): p. 1009-23. 
 27
59. Nolsoe, R.L., et al., Association of a microsatellite in FASL to type II 
diabetes and of the FAS-670G>A genotype to insulin resistance. Genes 
Immun, 2006. 7(4): p. 316-21. 
60. Ayala, J.E., et al., Considerations in the design of hyperinsulinemic-
euglycemic clamps in the conscious mouse. Diabetes, 2006. 55(2): p. 390-7. 
61. Fisher, S.J. and C.R. Kahn, Insulin signaling is required for insulin's direct 
and indirect action on hepatic glucose production. J Clin Invest, 2003. 
111(4): p. 463-8. 
 
 
 28
5 RESULTS 
 
5.1 Deletion of Fas (CD95) in adipocytes relieves adipose tissue 
inflammation and hepatic manifestations of obesity 
Stephan Wueest, Reto A. Rapold, Desiree M. Schumann, Julia M. Rytka, 
Anita Schildknecht, Alexander V. Chervonsky, Assaf Rudich, Eugen J. 
Schoenle, Marc Y. Donath, Daniel Konrad. Submitted 
 
 
5.2 Basal lipolysis, not the degree of insulin resistance, 
differentiates large from small isolated adipocytes in high-fat fed mice 
Stephan Wueest, Reto A. Rapold, Julia M. Rytka, Eugen J. Schoenle, 
Daniel Konrad. Diabetologia published online 
 
Publications are attached in the appendix. 
 29
6 DISCUSSION 
White adipose tissue (WAT) plays an important role in the 
pathogenesis/development of insulin resistance. In obesity, excess storage 
of triglycerides leads to a “dysfunction” of adipocytes, leading to increased 
secretion of several adipocytokines (TNF-α, IL-1β, IL-6 and MCP-1 e.g.) 
and free fatty acids (FFA). Increased secretion of these pro-inflammatory 
cytokines and FFA can lead to local and/or systemic insulin resistance. The 
altered secretion pattern of these factors is mediated by inflammatory cells 
that infiltrate adipose tissue in obesity (e.g. macrophages), and by the 
modified function of (hypertrophic) adipocytes. 
Although hypertrophic adipocytes isolated from obese subjects 
secrete more inflammatory cytokines compared to small adipocytes [21], we 
found no difference in insulin sensitivity between small and large adipocytes 
harvested from the same fat pad. However, large adipocytes have a higher 
rate of basal lipolysis, therefore releasing more FFA into the tissue and the 
circulation. Those results suggest that the degree of cellular hypertrophy is 
not a direct determinant of the severity of adipocyte insulin resistance. More 
likely, increased insulin resistance in adipocytes of HFD-fed mice might 
rather be the consequence of an increased release of pro-inflammatory 
cytokines and/or FFA of large adipocytes. Small and large adipocytes are 
affected in the same way, as both are exposed to the same “milieu”, and 
therefore show the same degree of insulin resistance. The reason for the 
increased release of FFA and pro-inflammatory cytokines from large and 
hypertrophic adipocytes needs to be further elucidated. 
Fas (CD95), a member of the tumour necrosis-factor super family, is 
a cell membrane receptor that can trigger apoptosis. However, recent 
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findings in several cells like fibroblasts and pancreatic β-cells also point 
towards an inflammatory role of the Fas signalling pathway. Accordingly, 
activation of the Fas signalling pathway in adipocytes leads to increased 
expression of IL-6 and KC (IL-8), and therefore may contribute to 
inflammatory pathways that are activated in obesity. Increased expression 
of the Fas receptor in WAT of obese and diabetic subjects and in isolated 
adipocytes in mouse models of insulin resistance suggests a role for Fas 
activation in adipocytes in the pathogenesis of insulin resistance. 
Interestingly, Fas seems to be a target (it can be up-regulated in adipocytes 
by pro-inflammatory cytokines like TNF-α or IL-1β) and a positive mediator 
(it can increase secretion of pro-inflammatory cytokines from adipose 
tissue) of the low grade inflammation that occurs in obesity/insulin 
resistance. Adipocyte-specific Fas-knockout (AFasKO) mice showed 
increased adipocyte and hepatic insulin sensitivity compared to wildtype 
littermates, further suggesting a role for adipocyte-expressed Fas in 
obesity-induced insulin resistance.  
In conclusion, excess energy intake leads to obesity and metabolic 
changes in adipose tissue. “Dysregulated” adipocytes in obesity secrete 
increased levels of pro-inflammatory factors, therefore contributing to the 
development of local and/or systemic insulin resistance. Large, lipid loaded 
adipocytes secrete higher amount of FFA, which can negatively affect 
insulin sensitivity. In addition, changes in secretion pattern of adipokines 
and cytokines, mediated e.g. by increased Fas activation in adipocytes, can 
lead to local and systemic insulin resistance. Hence, blocking the Fas 
signaling pathway in adipose tissue might be a promising target to reduce 
inflammatory processes induced by obesity. Moreover, reducing the 
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hypertrophic response of adipocytes to energy overload could reduce 
metabolic complications provoked by obesity. 
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7 APPENDIX 
7.1 Abbreviations 
AFasKO Adipocytes specific Fas knockout  
Akt  v-akt murine thymoma viral oncogene (PKB) 
ASK1  Apoptosis signaling kinase 1 
cAMP  Cyclic adenosine monophosphate 
C/EBP  CCAATT enhancer-binding protein 
CD95  Cluster of differentiation 95, Fas receptor 
Daxx  Death domain-associated protein 
DISC  Death inducing signalling complex 
ER  Endoplasmic reticulum 
ERK  Extracellular-signal related kinase 
FABP4  Fatty acid binding protein 4 
FADD  Fas-associated death domain 
Fas-def Total body Fas deficient 
FasL  Fas ligand 
FFA  Free fatty acid 
FLIP  FLICE (caspase 8) inhibitory protein 
G6Pase Glucose-6-phosphatase 
GLUT2 Glucose transporter 2 
GLUT4 Glucose transporter 4 
HFD  High fat diet 
HSL  Hormone sensitive lipase 
IL-10  Interleukin 10 
IL-1α  Interleukin 1α 
IL-1β  Interleukin 1β 
IL-6  Interleukin 6 
IL-8  Interleukin 8 
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ipGTT  Intra-peritoneal glucose tolerance test  
ipITT  Intra-peritoneal insulin tolerance test  
ipPTT  Intra-peritoneal pyruvate tolerance test  
IRS  Insulin receptor substrate 
JNK  C-Jun N-terminal kinase  
KC  Mouse IL-8 analogue 
LPL  Lipoprotein lipase 
MAPK  Mitogen activated protein kinase 
MCP-1  Monocyte chemo attractant protein 1 
mRNA  Messenger ribonucleic acid 
NAFLD Non-alcoholic fatty liver disease 
NF-κB  Nuclear factor-kappa B  
PEPCK Phosphoenolypyruvate carboxykinase 
PI3-K  Phosphatidylinositol 3-kinase 
PIP3  Phosphatidylinositol (3,4,5)-triphosphate 
PKA  Protein kinase A 
PKB  Protein kinase B 
PPARγ Proliferator-activator receptor γ 
PTEN  Phosphatase and tensin homologue 
Ser  Serine 
SOCS  Suppressor of cytokine signalling 
SVF  Stromal vascular fraction 
TNF-α  Tumour necrosis factor-alpha 
Tyr  Tyrosine 
UPR  Unfolded protein response 
WAT  White adipose tissue 
WT  Wild-type 
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